[go: up one dir, main page]

WO2010027830A3 - Methods for modulation of connective tissue growth factor expression - Google Patents

Methods for modulation of connective tissue growth factor expression Download PDF

Info

Publication number
WO2010027830A3
WO2010027830A3 PCT/US2009/054974 US2009054974W WO2010027830A3 WO 2010027830 A3 WO2010027830 A3 WO 2010027830A3 US 2009054974 W US2009054974 W US 2009054974W WO 2010027830 A3 WO2010027830 A3 WO 2010027830A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
compound
connective tissue
tissue growth
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/054974
Other languages
French (fr)
Other versions
WO2010027830A2 (en
Inventor
Nicholas M. Dean
J. Gordon Foulkes
Niall O'donnell
Gregory Hardee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excaliard Pharmaceuticals Inc
Original Assignee
Excaliard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excaliard Pharmaceuticals Inc filed Critical Excaliard Pharmaceuticals Inc
Publication of WO2010027830A2 publication Critical patent/WO2010027830A2/en
Publication of WO2010027830A3 publication Critical patent/WO2010027830A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides an improved method for reducing scarring resulting from wound healing in a subject in need thereof and treating fibrotic diseases and neoplastic diseases, which comprises administering to the subject a modified antisense compound which inhibits expression of connective tissue growth factor wherein the modified compound is administered to a delivery system which enhances uptake of the compound into and/or increases residence time of the compound in the subject's skin.
PCT/US2009/054974 2008-08-25 2009-08-26 Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases Ceased WO2010027830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19018408P 2008-08-25 2008-08-25
US61/190,184 2008-08-25

Publications (2)

Publication Number Publication Date
WO2010027830A2 WO2010027830A2 (en) 2010-03-11
WO2010027830A3 true WO2010027830A3 (en) 2010-04-29

Family

ID=41797787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054974 Ceased WO2010027830A2 (en) 2008-08-25 2009-08-26 Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases

Country Status (1)

Country Link
WO (1) WO2010027830A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688987B2 (en) 2008-08-25 2017-06-27 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN108165548B (en) 2008-09-22 2022-10-14 菲奥医药公司 Reduced size self-delivering RNAi compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
KR102453078B1 (en) 2010-03-24 2022-10-11 피오 파마슈티칼스 코프. Rna interference in dermal and fibrotic indications
CN103200945B (en) 2010-03-24 2016-07-06 雷克西制药公司 RNA interference in ocular syndromes
KR101249041B1 (en) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 Pharmaceutical composition using connective-tissue growth factor
MX365647B (en) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf).
US8802839B2 (en) 2011-07-15 2014-08-12 Fibrogen, Inc. Connective tissue growth factor antisense oligonucleotides
CN113151180A (en) 2013-12-02 2021-07-23 菲奥医药公司 Immunotherapy of cancer
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
KR102689262B1 (en) 2014-09-05 2024-07-30 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
WO2016205226A1 (en) * 2015-06-15 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180300A1 (en) * 1998-12-14 2003-09-25 Grotendorst Gary R. Connective tissue growth factor fragments and methods and uses thereof
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180300A1 (en) * 1998-12-14 2003-09-25 Grotendorst Gary R. Connective tissue growth factor fragments and methods and uses thereof
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANTOS ET AL.: "Intraocular Delivery of Oligonucleotides.", CURR PHARM BIOTECH FEBRUARY, vol. 6, no. 1, 2005, pages 7 - 15 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688987B2 (en) 2008-08-25 2017-06-27 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

Also Published As

Publication number Publication date
WO2010027830A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2010027830A3 (en) Methods for modulation of connective tissue growth factor expression
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2007100675A3 (en) Collagenase for treating cellulite
GB2465902A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2009134967A3 (en) Use of nucleic acids with reduced pressure therapy for treating wounds
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
EA201070740A1 (en) METHOD OF TREATING BONE FRACTURE WITH ANTIBODIES AGAINST SKLEROSTIN
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012078561A3 (en) A drape having microstrain inducing projections for treating a wound site
WO2005102307A3 (en) Beneficial effects of increasing local blood flow
MXPA02000721A (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation.
NZ603028A (en) Tfpi inhibitors and methods of use
WO2012018545A3 (en) Systems and methods for treatment of sleep apnea
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
EP2292226A3 (en) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
WO2010151778A3 (en) Topical compositions and methods for wound care
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2005072057A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO2004110420A8 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
WO2003090662A3 (en) Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09812034

Country of ref document: EP

Kind code of ref document: A2